




FIG. 1

2/17




FIG. 2




FIG. 3




FIG. 4




FIG. 5




FIG. 6




FIG. 7

8/17




FIG. 8




FIG. 9

10/17




FIG. 10




FIG. 11




FIG. 12




FIG. 13

14/17





FIG. 14A



16/17




FIG. 15

G/GEJ IO Refractory Patients Treated
with DKN-01 + Pembrolizumab




FIG. 16B

G/GEJ IO Refractory Patients Treated
with DKN-01 + Pembrolizumab




FIG. 16A